uniQure N.V (UQ1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, uniQure N.V (UQ1) has a cash flow conversion efficiency ratio of -0.256x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-38.24 Million ≈ $-44.71 Million USD) by net assets (€149.34 Million ≈ $174.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See UQ1 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
uniQure N.V - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how uniQure N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data.
uniQure N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of uniQure N.V ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ShenZhen Kondarl Group Co Ltd
SHE:000048
|
0.056x |
|
Azad Engineering Limited
NSE:AZAD
|
-0.050x |
|
Macmahon Holdings Ltd
AU:MAH
|
0.187x |
|
Hunan TV & Broadcast Intermediary Co Ltd
SHE:000917
|
-0.008x |
|
Sihui Fuji Electronics Technology Co Ltd
SHE:300852
|
0.026x |
|
Changbai Mountain Tourism Co Ltd
SHG:603099
|
-0.028x |
|
Chagee Holdings Limited American Depositary Shares
NASDAQ:CHA
|
0.024x |
|
Shanxi Huaxiang Group Co Ltd
SHG:603112
|
-0.001x |
Annual Cash Flow Conversion Efficiency for uniQure N.V (2016–2025)
The table below shows the annual cash flow conversion efficiency of uniQure N.V from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market value of uniQure N.V.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €198.90 Million ≈ $232.54 Million |
€-177.96 Million ≈ $-208.06 Million |
-0.895x | -103.31% |
| 2024-12-31 | €-6.75 Million ≈ $-7.89 Million |
€-182.73 Million ≈ $-213.63 Million |
27.063x | +3951.28% |
| 2023-12-31 | €207.67 Million ≈ $242.79 Million |
€-145.93 Million ≈ $-170.61 Million |
-0.703x | -130.59% |
| 2022-12-31 | €476.01 Million ≈ $556.50 Million |
€-145.06 Million ≈ $-169.59 Million |
-0.305x | -163.05% |
| 2021-12-31 | €595.78 Million ≈ $696.52 Million |
€287.96 Million ≈ $336.65 Million |
0.483x | +187.44% |
| 2020-12-31 | €243.91 Million ≈ $285.15 Million |
€-134.83 Million ≈ $-157.63 Million |
-0.553x | -80.96% |
| 2019-12-31 | €323.06 Million ≈ $377.69 Million |
€-98.68 Million ≈ $-115.37 Million |
-0.305x | +27.85% |
| 2018-12-31 | €179.61 Million ≈ $209.98 Million |
€-76.04 Million ≈ $-88.90 Million |
-0.423x | +41.14% |
| 2017-12-31 | €89.36 Million ≈ $104.47 Million |
€-64.27 Million ≈ $-75.14 Million |
-0.719x | +36.60% |
| 2016-12-31 | €63.63 Million ≈ $74.39 Million |
€-72.19 Million ≈ $-84.40 Million |
-1.134x | -- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more